MA-BATTERY-VENTURES
17.4.2024 12:01:33 CEST | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, announced the acquisition of Labguru (BioData Inc.), the life-science laboratory-data platform, from Holtzbrinck Digital. Terms were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417562351/en/
Labguru provides a comprehensive laboratory data-management hub for planning and tracking; documenting experiments; streamlining lab logistics; and sharing results across teams and organizations. Labguru’s easy-to-use, cloud-based, research-to-production life-science platform combines an Electronic Lab Notebook (ELN), a Laboratory Information Management System (LIMS) and a set of informatics tools to enable and enhance research and production. Labguru is trusted by hundreds of thousands of scientists across the biotechnology, pharmaceutical and advanced-industry segments, as well as researchers at global academic and research institutions.
Labguru will join Battery’s Titian Software to create a global organization that offers an end-to-end solution across life sciences and laboratory applications from research to production, spanning the entire workflow from ELN to inventory and sample management, research, testing and QC workflows.
“Together Titian and Labguru will use the investment by Battery to further support organic growth as well as shape the direction of the group’s future acquisitions, in fulfilling the group vision to become the one-stop shop of the global life-science software market,” said Battery General Partner Jesse Feldman.
“We are excited to bring together Titian and Labguru and to work with the companies’ leaders to provide an integrated laboratory and sample-management offering to researchers,” Feldman said. “The two companies already serve researchers across multiple disciplines at the forefront of science, and we look forward to expanding how we serve our customers.”
Labguru’s executive team, including CEO Ariel Yarnitsky and founder and CTO Jonathan Gross, will remain in their current roles, working alongside the Titian executive team following the transaction.
“We’re excited to join forces with Battery, a long-standing investor with domain expertise across life-science informatics and laboratory automation and leverage their vast experience during Labguru’s next growth phase,” said Yarnitsky. “Specifically, Labguru’s mission to build a leading solution catering to the broad needs of scientists in one coherent and easy-to-use platform becomes even more exciting by joining hands with Titian and with the strong support of Battery. Between the additional capital from Battery and the product and cultural fit with Titian, we could not think of a more suitable partner to propel Labguru forward.”
Founder Gross added: “Partnering with Battery and Titian will accelerate our ability to leverage technology, experience and insights to effectively widen the scope of our platform, benefiting science and scientists. This is an important and dramatic step in Labguru’s journey. Further, with Battery Ventures’ long-standing experience investing in data and AI companies, we have found a valuable partner to help shape our vision as we continue building on Labguru’s suite of artificial intelligence tools.”
Titian Software Founder and Chief Product Officer Edmund Wilson added, “We are delighted to partner with Labguru. Our companies share a common commitment to providing state-of-the-art solutions to the life sciences community, delivered by staff who offer tremendous domain expertise.”
Holtzbrinck Digital played a crucial role in Labguru's development and success. Their vision and support have been instrumental in the company's fast growth and positioning as a tier-1 lab-management software company. "We are extremely happy with Labguru's development over the last years and are proud of the strides we've made together. Finding a partner like Battery, who shares our commitment to innovation and excellence, marks a thrilling next chapter for Labguru," said Marc-Orell Dedorath, head of group M&A at Holtzbrinck.
“We are thrilled to unite two major forces in a market that's only beginning to realize its vast potential,” added Justin Rosner, a principal at Battery. “We look forward to working with the Labguru and Titian teams as we embark on this journey together."
About Labguru (BioData Inc.)
Labguru (BioData Inc.) was founded in 2007 and is the developer of a secure, cloud-based laboratory data management platform for life science research and industry. Labguru is an all-in-one platform that streamlines laboratory operations by recording and managing data and inventory, offering molecular biology and chemistry tools, enabling lab automation, and providing data-driven, AI-assisted insights for increased efficiency. As a trusted tool for more than 120,000 scientists worldwide, we empower the digitalization efforts of customers ranging from start-ups to global life science organizations. To learn more about Labguru, visit www.labguru.com.
About Titian Software
Titian Software was founded in 1999 and is a leading provider of sample management software solutions, catering to the unique needs of research laboratories, biobanks, and pharmaceutical companies worldwide. Titian's Mosaic Sample Management Software encompasses a comprehensive suite of tools for sample tracking, inventory management, and workflow automation. Mosaic empowers laboratories to efficiently manage vast repositories of samples, including compounds, biological materials, and clinical specimens while ensuring data integrity and traceability throughout the sample lifecycle. www.titian.co.uk.
About Battery Ventures
Battery partners with exceptional founders and management teams, developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT, and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Tel Aviv; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com, and find a complete list of Battery's portfolio companies here.
About Holtzbrinck Digital
Holtzbrinck Digital manages the investments of the Holtzbrinck Publishing Group in digital startups in the science and education sector, as well as other areas of strategic importance. Holtzbrinck Digital supports them in their development with expertise, resources, and a long-term commitment, enabling the companies to achieve the best possible development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417562351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom